Author: Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy
Title: Interferon-? Inhibits Ebola Virus Infection Document date: 2015_11_12
ID: 10bu7iwg_35
Snippet: Filovirus pathogenesis has been investigated through the use of a variety of different animal models, including mice, guinea pigs, hamsters, and non-human primates (NHPs) [70] [71] [72] . These various model organisms offer different advantages for studying EBOV pathogenesis and assessing novel antiviral treatments. While NHPs are considered the most representative model for EBOV infection as they display very similar symptoms to those observed i.....
Document: Filovirus pathogenesis has been investigated through the use of a variety of different animal models, including mice, guinea pigs, hamsters, and non-human primates (NHPs) [70] [71] [72] . These various model organisms offer different advantages for studying EBOV pathogenesis and assessing novel antiviral treatments. While NHPs are considered the most representative model for EBOV infection as they display very similar symptoms to those observed in humans [72] , they are expensive and, ethically, the use of these animals should be limited to late phase pre-clinical studies. In contrast, infection of mice with MA-EBOV serves as a good, genetically manipulatable small animal model for early phase evaluation of vaccines and therapeutic interventions, allowing assessment of their impact on viral pathogenesis. Our definitive evidence of IFNγ efficacy in this small animal model paves the way for future NHP studies to further assay the anti-EBOV properties of IFNγ.
Search related documents:
Co phrase search for related documents- animal model and definitive evidence: 1, 2
- animal model and different animal model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- animal model and early phase: 1, 2, 3, 4, 5, 6
- animal model and ebov infection: 1, 2, 3
- animal model and EBOV pathogenesis: 1
- animal model and guinea pig: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- animal model and human observe: 1
- animal model and late phase: 1, 2, 3
- animal model and model organism: 1, 2, 3
- animal model and non human primate: 1, 2, 3, 4, 5, 6
- animal model and novel antiviral treatment: 1
- animal model and pre clinical study: 1, 2
- animal model and representative model: 1, 2, 3, 4, 5, 6
- animal model and similar symptom: 1
- animal model and small animal model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- animal model and therapeutic intervention: 1, 2, 3, 4, 5
- animal model and therapeutic intervention vaccine: 1
- animal model and viral pathogenesis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- animal model and viral pathogenesis impact: 1, 2
Co phrase search for related documents, hyperlinks ordered by date